Tema Oncology ETF Rating $38.12 0.00 (0.00%) As of 05/22/2026 03:59 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock Tema Oncology ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CANC Aggregate RatingModerate Buy 2.76Holdings in CANC have an aggregate rating of Moderate Buy based on 401 analyst ratings issued in the past year covering 23 companies (69.7% of the portfolio).CANC Aggregate Price Target$38.12High Prediction$38.12Average Prediction$38.12Low Prediction$38.12Holdings in CANC have an aggregate price target of $38.12 and a range of $38.12 to $38.12 covering 23 companies (69.7% of the portfolio).CANC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy18 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Oncology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 23 CANC Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings7.40%RVMDRevolution Medicines$151.562.6504 of 5 stars3.00$111.35 -26.5%21Positive News4.50%LLYEli Lilly and Company$1,066.59+0.1%4.82 of 5 stars2.87$1,220.37 14.4%30Trending NewsAnalyst Forecast4.29%RHHBYRoche$53.341.8449 of 5 stars2.45$51.50 -3.4%113.84%COGTCogent Biosciences$32.672.3182 of 5 stars2.86$43.73 33.8%143.73%IMNMImmunome$21.663.4533 of 5 stars2.92$32.82 51.5%12Positive NewsGap Up3.72%CELCCelcuity$138.232.0858 of 5 stars2.83$149.30 8.0%123.54%MRKMerck & Co., Inc.$122.55+0.1%4.3901 of 5 stars2.68$128.18 4.6%193.46%BMYBristol Myers Squibb$59.51+0.1%4.7416 of 5 stars2.37$61.31 3.0%19Positive News3.19%NUVLNuvalent$102.123.2871 of 5 stars2.94$140.29 37.4%183.11%LEGNLegend Biotech$29.374.2094 of 5 stars2.67$59.00 100.9%15Gap Down2.86%EXELExelixis$50.152.3955 of 5 stars2.39$47.35 -5.6%23Insider Trade2.84%BBIOBridgeBio Pharma$69.123.5122 of 5 stars2.88$88.90 28.6%25Gap Up2.82%ABBVAbbVie$216.02+0.1%4.9069 of 5 stars2.88$253.43 17.3%25Positive News2.70%JNJJohnson & Johnson$234.67+0.1%4.3386 of 5 stars2.74$253.04 7.8%27Positive News2.56%CGONCG Oncology$64.252.761 of 5 stars2.71$81.73 27.2%142.48%GMABGenmab A/S$26.873.8584 of 5 stars2.83$39.07 45.4%122.29%ZLABZai Lab$18.613.8217 of 5 stars2.63$45.83 146.3%82.13%IDYAIDEAYA Biosciences$29.103.239 of 5 stars2.82$50.69 74.2%17Analyst Forecast2.12%AMGNAmgen$339.304.1698 of 5 stars2.48$355.19 4.7%31Positive NewsAnalyst Upgrade2.00%ONCBeOne Medicines$310.254.1624 of 5 stars2.80$389.15 25.4%151.53%ZYMEZymeworks$25.613.1975 of 5 stars2.91$38.00 48.4%111.30%HALOHalozyme Therapeutics$68.323.987 of 5 stars2.50$80.67 18.1%12Positive News1.24%URGNUrogen Pharma$28.893.357 of 5 stars2.80$36.67 26.9%10Gap Up This page (NASDAQ:CANC) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
